PYC Therapeutics Completes $47m Retail Entitlement Offer, Boosting Capital for RNA Programs

The latest announcement is out from PYC Therapeutics Limited ( (AU:PYC) ).

PYC Therapeutics Limited has completed the retail component of its pro rata accelerated non-renounceable entitlement offer, raising about $47 million at $1.50 per new share. The offer saw applications for roughly 31 million shares, including additional applications of up to 100% of entitlements, representing a 40% take-up by eligible retail shareholders.

New shares from the retail offer are scheduled to be issued and begin trading on the ASX in early March, ranking equally with existing shares. Around 11 million of the approximately 46 million untaken retail shares will be issued to underwriters, while the remaining roughly 35 million may be placed with new or existing investors within three months at not less than the original offer price.

This retail raise follows an earlier institutional component and placement that secured about $537 million, significantly strengthening PYC’s capital position. The combined funding bolsters the company’s ability to advance its RNA therapeutic programs and may enhance its standing in the competitive genetic medicines sector.

The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on precision medicine for patients with genetic diseases lacking treatment options. The company develops a new generation of RNA therapies using a proprietary drug delivery platform to enhance potency, targeting monogenic diseases with strong prospects for clinical success.

Average Trading Volume: 840,221

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$1.41B

See more insights into PYC stock on TipRanks’ Stock Analysis page.